A hospital based study on the surgical outcomes of thyroid malignancies

R. Anuj Srinivasan, K. Rajachidambaram*, P. Karthick, M. Vijay Anand

ABSTRACT

Background: Thyroid cancer is a heterogeneous disease that affects all age groups. The tumors are found to be more aggressive in the elderly. The distribution of these cancers in India continues to remain uncertain. The impact of geographic locations in the incidence of thyroid malignancies is yet to be explored. This study was done to estimate the prevalence and distribution of thyroid cancers.

Methods: This hospital based retrospective study was done at the Department of Surgery of our medical college hospital. About 50 medical records of patients diagnosed with thyroid cancers at our hospital were analyzed. Data on clinical examination, ultrasound findings and histopathology findings were documented.

Results: Out of the 50 patients studied 16 patients had dysphagia, eight patients had dyspnoea and 24 patients had regional metastasis. The most common surgery done for the primary cancer is total thyroidectomy. Hemithyroidectomy was done in 10 patients with SNG, out of which one patient had discrete lymph node per operatively and node dissection was carried out.

Conclusions: TSH suppressive doses are recommended for all patients with papillary and follicular thyroid cancers. A cohort study to analyze the survival outcomes of the patients treated with both the surgical modalities will give an insight into the management of thyroid malignancies.

Keywords: Papillary carcinoma, Neck dissection, Thyroidectomy, Multinodular goiter

INTRODUCTION

Thyroid carcinoma is a fascinating tumor because of the diversity in tumor presentation and behavior. It is a relatively rare tumor, though it is the most common endocrine malignancy. Despite the fact that majority of the thyroid disorders are hypothyroidism and other hormone imbalances, the incidence of thyroid malignancy is on the rise in the last few decades. This increase in the incidence could be attributed to routine head and neck examinations by physical examinations and early detection through improved diagnostic and investigative procedures. Thyroid cancer is a heterogeneous disease that affects all age groups. The tumors are found to be more aggressive in the elderly. Females have an increased preponderance to thyroid malignancies, and among all the types, papillary carcinoma is the most common type.

The management of thyroid cancers continues to be a challenge, due to the survival rates of differentiated cancers. Therefore, irrespective of the type or extent of treatment, a high index of suspicion is required for the diagnosis of these cancers. Undifferentiated thyroid cancers continue to have a dismal prognosis. Anaplastic thyroid carcinoma remains one of the most difficult human malignancies to treat and is highly lethal. Medullary thyroid cancer is one of the best characterized solid malignancies.
While most of the cancers can be treated surgically, the role of alternative therapies like chemotherapy, radiation therapy and iodine irradiation needs to be evaluated. The British Thyroid Association came up with set recommendations as a guideline for the management of thyroid cancers in 2014. Accordingly, ultrasound imaging and fine needle aspiration cytology (FNAC) is the mainstay in diagnosis of thyroid malignancies. Magnetic resonance imaging (MRI) or computerized tomography (CT) may be done in suspected cases to assess the extension of the tumor and involvement of the adjacent tissues like vocal cord, etc. The association has brought out guidelines for the surgical management of these thyroid cancers. The decision on differentiating between the need for a total thyroidectomy or hemi thyroidectomy has been well outlined by these guidelines.

In consequence to the British guidelines, the American Thyroid Association brought out their guidelines in 2015 with an emphasis on the need to monitor the Thyroid Stimulating Hormone (TSH) levels. It also highlights the mandate for monitoring Thyroglobulin (Tg) levels.

As far as the available literature goes, there are no separate guidelines in India for the therapeutic management of thyroid malignancies. The knowledge base about thyroid malignancies is continuously evolving and an in depth research will help improve the management modalities in India; and may lead to better treatment options in the future.

Objectives

- To evaluate the role of TSH suppressive treatment with thyroxine for malignancies of thyroid.
- The assess the outcome of patients treated for thyroid malignancies

**METHODS**

**Study setting**

This retrospective study of hospital records was done in the Department of General Surgery of our medical college hospital with a diagnosis of thyroid cancers between January 2008 and September 2010.

**Study population**

The medical records of all patients with thyroid cancers admitted in our medical college hospital from January 2008 to September 2010 were selected for the study. Patients who had thyroid carcinoma on histopathology examination were included in the Study.

**Ethical approval**

Approval from the Institutional Ethics Committee was obtained prior to the commencement of the study.

**Data collection**

Data regarding the clinical examination and indirect laryngoscopy (done by E.N.T. Surgeons) for evaluation of vocal cord status were recorded. Ultrasound findings of the neck and fine needle aspiration cytology (FNAC) findings were documented. Patients who were symptomatic or had a positive or indeterminate FNAC were subjected to surgery. The relevant information was tabulated and used for analysis. After Surgery, all patients with differentiated thyroid cancers received suppressive dose of thyroxine. The observations were compared with the current literature on thyroid cancers and conclusions were drawn.

**Data analysis**

Data was entered and analyzed using Microsoft Excel 2007 spreadsheet. The prevalence and determinants of thyroid cancers were expressed as percentages.

**RESULTS**

All patients with thyroid cancer proven by histopathology admitted between January 2008 and September 2010 were included in the study. The study group consisted of 50 patients. The sex distribution of the study participants is given in Figure 1. About 90% of the participants were females while 10% were males.

![Figure 1: Sex distribution of the study participants.](image-url)
Table 1: Findings of patients with thyroid malignancies.

| Symptoms                      | Papillary | Follicular | Medullary | Anaplastic | Total | %  |
|-------------------------------|-----------|------------|-----------|------------|-------|----|
| MNG                           | 24        | 2          | 2         | 2          | 30    | 60 |
| SNG                           | 15        | 3          | 2         | 0          | 20    | 40 |
| Dysphagia                     | 3         | 3          | 0         | 2          | 8     | 16 |
| Dyspnea                       | 2         | 0          | 0         | 2          | 4     | 8  |
| Hoarseness                    | 2         | 0          | 0         | 2          | 4     | 8  |
| Regional lymph node metastasis| 22        | 0          | 2         | 0          | 24    | 48 |
| Distant Metastasis            | 1         | 0          | 0         | 0          | 1     | 2  |

Figure 2: Age distribution for patients with thyroid cancer.

Figure 3: Frequency of patients with thyroid cancer associated with gender.

**Treatment of thyroid malignancy**

The most common surgery done for the primary cancer is total thyroidectomy. Hemithyroidectomy was done in 10 patients with SNG, out of which one patient had discrete lymph node per operatively and node dissection was carried out. Out of 24 patients, 20 with palpable cervical node were subjected to neck node dissection on the involved side (i.e. the side with palpable nodes) (Table 2).
Table 2: Distribution of treatment for patients with thyroid malignancy.

| Types of surgery       | Papillary | Follicular | Medullary | Anaplastic |
|------------------------|-----------|------------|-----------|------------|
| Thyroidectomy          | 24        | 5          | 3         | 0          |
| Total thyroidectomy    | 24        | 5          | 3         | 0          |
| Subtotal thyroidectomy | 4         | 0          | 0         | 0          |
| Hemi thyroidectomy     | 9         | 0          | 1         | 0          |
| Neck dissection        | 3         | 0          | 0         | 0          |
| Anterior neck dissection| 1       | 0          | 1         | 0          |
| MRND/FND               | 18        | 0          | 0         | 0          |

Out of the 32 patients in which total thyroidectomy was done, 4 patients had post-op hypocalcemia, which was treated with calcium gluconate. The patients recovered and remained asymptomatic during follow up. Patients with undifferentiated anaplastic carcinoma were treated with radiotherapy and chemotherapy.

All patients with differentiated thyroid cancers were followed postoperatively with suppressive doses of thyroxine.

DISCUSSION

Papillary carcinoma of thyroid is the most common thyroid malignancy in the study group. Usually 2/3rd of patients with differentiated thyroid carcinoma have disease localized to thyroid at presentation.

In the study group, 60.3% patients have disease localized to thyroid. The most common symptom at presentation for all thyroid cancers is a thyroid swelling. About 60% of the patients presented with multinodular goiter. Total thyroidectomy is now advocated for all well differentiated thyroid cancers and medullary thyroid cancer. Central compartmental dissection is to be done for all mediullary thyroid cancers. Modified radical neck dissection is recommended only in the presence of metastatic cervical lymph nodes. In the study group, total thyroidectomy was the most common surgery performed. Out of 24 patients with palpable cervical lymph node, 20 (83.3%) underwent neck node dissection on the involved side.

A combination of radiotherapy and chemotherapy (with Adriamycin) is the most appropriate therapy for undifferentiated carcinomas. TSH Suppressive doses of levothyroxine are recommended for all patients with papillary and follicular thyroid cancers. This was followed for all patients in the study group with differentiated thyroid cancers. The goal of this therapy is to maintain serum TSH concentration of 0.1 Mu / L or less.

CONCLUSION

This study has explored the role of thyroidectomy and neck dissection in the surgical management of thyroid malignancies. TSH suppressive doses are recommended for all patients with papillary and follicular thyroid cancers. Life expectancy of patients following surgery could not be ascertained due to the short duration of the study. A cohort study to analyze the survival outcomes of the patients treated with both the surgical modalities will give an insight into the management of thyroid malignancies.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: The study was approved by the Institutional Ethics Committee

REFERENCES

1. Stewart BW, Wild CP. World cancer report 2014. Lyon: International Agency for Research on Cancer; 2014.
2. Wartofsky L. Increasing world incidence of thyroid cancer: increased detection or higher radiation exposure? Hormones (Athens). 2010;9:103–8.
3. Ahn HS, Kim HJ, Welch HG. Korea's thyroid-cancer "epidemic": screening and overdiagnosis. N Engl J Med. 2014;371:1765–7.
4. Atlanta, GA: American Cancer Society; 2015. What are the risk factors for thyroid cancer? Available at: http://www.cancer.org/cancer/thyroid-cancer/detailedguide/thyroid-cancer-risk-factors. Accessed on 1st May 2016.
5. Schmid D, Behrens G, Jochem C, Keimling M, Leitzmann M. Physical activity, diabetes, and risk of thyroid cancer: a systematic review and meta-analysis. Eur J Epidemiol. 2013;28:945–58.
6. Zhao ZG, Guo XG, Ba CX, Wang W, Yang YY, Wang J, et al. Overweight, obesity and thyroid cancer risk: a meta-analysis of cohort studies. J Int Med Res. 2012;40:2041–50.
7. Kitahara CM, Linet MS, Beane Freeman LE, Check DP, Church TR, Park Y, et al. Cigarette smoking, alcohol intake, and thyroid cancer risk: a pooled analysis of five prospective studies in the United States. Cancer Causes Control. 2012;23:1615–24.
8. Cho YA, Kim J. Thyroid cancer risk and smoking status: a meta-analysis. Cancer Causes Control. 2014;25:1187–95.
9. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. Lyon: International Agency for Research on Cancer; 2013. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11. Available at: http://globoCAN.iarc.fr. Accessed on 1st May 2016.
10. Allison PD. Survival analysis using the SAS: a practical guide. Cary, NC: SAS Institute Inc.; 1995.
11. Lyon: International Agency for Research on Cancer; 2013. Thyroid: ASR (W) per 100,000, all ages. Available at:globocan.iarc.fr/old/bar_sex_site.asp. Accessed on 1st May 2016.
12. Jung KW, Won YJ, Kong HJ, Oh CM, Cho H, Lee DH, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2012. Cancer Res Treat. 2015;47:127–41.
13. Farahati J, Bucsky P, Parlowsky T, Mader U, Reiners C. Characteristics of differentiated thyroid carcinoma in children and adolescents with respect to age, gender, and histology. Cancer. 1997;80:2156-62.
14. Rossing MA, Voigt LF, Wicklund KG, Daling JR. Reproductive factors and risk of papillary thyroid cancer in women. Am J Epidemiol. 2000;151:765–72.
15. Horn-Ross PL, Canchola AJ, Ma H, Reynolds P, Bernstein L. Hormonal factors and the risk of papillary thyroid cancer in the California Teachers Study cohort. Cancer Epidemiol Biomarkers Prev. 2011;20:1751–9.
16. Zeng Q, Chen GG, Vlantis AC, van Hasselt CA. Oestrogen mediates the growth of human thyroid carcinoma cells via an oestrogen receptor-ERK pathway. Cell Prolif. 2007;40:921–35.
17. Kumar A, Klinge CM, Goldstein RE. Estradiol-induced proliferation of papillary and follicular thyroid cancer cells is mediated by estrogen receptors alpha and beta. Int J Oncol. 2010;36:1067–80.
18. Manole D, Schildknecht B, Gosnell B, Adams E, Derwahl M. Estrogen promotes growth of human thyroid tumor cells by different molecular mechanisms. J Clin Endocrinol Metab. 2001;86:1072-7.